The Russian Direct Investment Fund (Russian Direct Investment Fund) expects that the Sputnik V vaccine will begin to be distributed in 2021, when 500 million people will use it. This candidate vaccine caused experts to question human trials and opaque data in August.
The Russian Direct Investment Fund (RDIF) and the Gamaleya Institute (part of the Russian Ministry of Health) announced that Preliminary data from clinical trials Your vaccine against covid-19, Sputnik 5, After 28 days from the first administration, it showed 91.4% efficacy, and after 42 days, it showed 95% or more efficacy.The candidate vaccine was approved only two months after the start of human trials (ie June), and due to The speed of these tests with opaque The data of the drug.
Both Russian institutions have proposed that each institution dose Will cost less than Ten dollars To the international market.Since it is a two-dose vaccine, its price will be lower than 20 dollars“Two or more times cheaper than other foreign vaccines based on messenger RNA technology [Moderna y Pfizer] They pointed out in a statement. The vaccine will be provided free of charge to Russian citizens.
RDIF has agreed to start using this technology to produce this “dehydrated” vaccine. Freeze-dried.They said that in this way, “it will be stored in 2 a 8ºC, Which will help transport to the international market, even to areas with inconvenient transportation and tropical climate.” The goal of the Russian Fund is to distribute vaccines to 500 million people From the beginning of 2021
The technical name of the vaccine is Gam-Covid-Vac Lyo (and renamed after the Soviet satellite), which is Doss adenovirus, Ad5 and Ad26 are both engineered using coronavirus genes.
The general manager of RDIF, Kirill Dmitriev, Emphasized that the vaccine developed by the Gamaleya Institute is “unique” because it uses two different human adenovirus vectors. “Compared with the vaccine using a single vector, it can provide a stronger and lasting immune response. [Oxford-AstraZeneca]”.
Dmitriev concluded: “Thanks to the agreements reached with manufacturers in India, Brazil, South Korea, China and four other countries, we are ready to market the artificial satellite V vaccine to the international market.”
Data from clinical trials
As of today, RDIF and Gamaleya Institute have been freed About the vaccine has been tested 40,000 volunteers: The second dose will receive 22,000 doses, and the second dose has been received by 19,000 people.
In this document, both organizations ensure Phase III clinical trial In Belarus, the United Arab Emirates, Venezuela and other countries, these drugs have been “approved and are in progress”, while India is undergoing phase II-III trials.
According to these data, there is no Negative Effects The vaccine was used throughout the investigation, although some volunteers suffered Ailment Examples include pain at the injection site and flu-like symptoms such as fever, weakness, fatigue, and headache.
During the clinical trial, an independent monitoring committee composed of Russian scientists is reviewing the safety of the vaccine. The Moscow Ministry of Health and Saffron Medicine (which the research institute has contracted) also actively collects data from the trial.